Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
This clinical trial is for men and women with Clonal Cytopenia of Undetermined Significance (CCUS).
The purpose of this research is to test the benefit and safety of Canakinumab. Canakinumab is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).
In this study, participants will be randomized to receive either receive Canakinumab or the placebo which will be given through an injection every three months. Randomization is like flipping a coin and there is a 50/50 chance of being assigned to either group.
Participation is expected to last up to 8 years (3 years for accrual and a minimum of 5 years of follow-up from accrual of last patient to observe the specified number of events).
Detailed eligibility will be reviewed when you contact the study team.